[1]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) Global Cancer Sta-tistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
Xia, C., Dong, X., Li, H., Cao, M., Sun, D., He, S., Yang, F., Yan, X., Zhang, S., Li, N. and Chen, W. (2022) Cancer Statistics in China and United States, 2022: Profiles, Trends, and Determinants. Chinese Medical Journal, 135, 584-590. https://doi.org/10.1097/CM9.0000000000002108
|
[3]
|
Cao, M.M., Li, H., Sun, D.Q., He, S.Y., Yan, X.X., Yang, F., Zhang, S.L., Xia, C.F., Lei, L., Peng, J. and Chen, W.Q. (2022) Current Cancer Burden in China: Epidemiology, Eti-ology, and Prevention. Cancer Biology & Medicine, 19, 1121-1138. https://doi.org/10.20892/j.issn.2095-3941.2022.0231
|
[4]
|
曹毛毛, 李贺, 孙殿钦, 何思怡, 雷林, 彭绩, 陈万青. 2000-2019年中国胃癌流行病学趋势分析[J]. 中华消化外科杂志, 2021, 20(1): 102-109.
|
[5]
|
左婷婷, 郑荣寿, 曾红梅, 张思维, 陈万青. 中国胃癌流行病学现状[J]. 中国肿瘤临床, 2017, 44(1): 52-58.
|
[6]
|
Zheng, Z., Yin, J., Liu, X.Y., Yan, X.S., Xu, R., Li, M.Y., Cai, J., Chen, G.Y., Zhang, J. and Zhang, Z.T. (2021) Current Indications for Endo-scopic Submucosal Dissection of Early Gastric Cancer. World Journal of Gastrointestinal Oncology, 13, 560-573. https://doi.org/10.4251/wjgo.v13.i6.560
|
[7]
|
中国抗癌协会胃癌专业委员会. 局部进展期胃癌围手术期治疗中国专家共识(2021版) [J]. 中华胃肠外科杂志, 2021, 24(9): 741-748.
|
[8]
|
Ychou, M., Boige, V., Pignon, J.P., Conroy, T., Bouché, O., Lebreton, G., Ducourtieux, M., Bedenne, L., Fabre, J.M., Saint-Aubert, B., Genève, J., Lasser, P. and Rougier, P. (2011) Perioperative Chemotherapy Compared with Surgery alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial. Journal of Clinical Oncology, 29, 1715-1721. https://doi.org/10.1200/JCO.2010.33.0597
|
[9]
|
Kang, Y.-K., Yook, J.H., Park, Y.-K., Kim, J., Ryu, M.-H., Rha, S.Y., et al. (2019) Phase III Randomized Study of Neoadjuvant Chemotherapy (CT) with Docetaxel(D), Oxaliplatin(O) and S-1(S) (DOS) Followed by Surgery and Adjuvant S-1, vs Surgery and Adjuvant S-1, for Resectable Advanced Gastric Cancer (GC) (PRODIGY). Annals of Oncology, 30, v876-v877. https://doi.org/10.1093/annonc/mdz394.032
|
[10]
|
Ji, J., Shen, L., Li, Z., Rha, S.Y., Liang, H., Liang, H., et al. (2019) Perioperative Chemotherapy of Oxaliplatin Combined with S-1 (SOX) versus Postoperative Chemotherapy of SOX or Oxaliplatin with Capecitabine (XELOX) in Locally Advanced Gastric Adenocarcinoma with D2 Gastrectomy: A Randomized Phase III Trial (RESOLVE Trial). Annals of Oncology, 30, 851-934. https://doi.org/10.1093/annonc/mdz394.033
|
[11]
|
Rosen, V.M., Guerra, I., McCormack, M., Nogueira-Rodrigues, A., Sasse, A., Munk, V.C. and Shang, A. (2017) Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel versus Non-Bevacizumab-Containing Therapies in Persistent, Re-current, or Metastatic Cervical Cancer. International Journal of Gynecologic Cancer, 27, 1237-1246. https://doi.org/10.1097/IGC.0000000000001000
|
[12]
|
Giuliano, M., Schettini, F., Rognoni, C., Milani, M., Jerusa-lem, G., Bachelot, T., De Laurentiis, M., Thomas, G., De Placido, P., Arpino, G., De Placido, S., Cristofanilli, M., Giordano, A., Puglisi, F., Pistilli, B., Prat, A., Del Mastro, L., Venturini, S. and Generali, D. (2019) Endocrine Treatment versus Chemotherapy in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer: A Systematic Review and Network Meta-Analysis. The Lancet Oncology, 20, 1360-1369. https://doi.org/10.1016/S1470-2045(19)30420-6
|
[13]
|
Damm, M., Efremov, L., Birnbach, B., Terrero, G., Kleeff, J., Mikolajczyk, R., Rosendahl, J., Michl, P. and Krug, S. (2021) Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer—A Systematic Review and Me-ta-Analysis. Cancers, 13, Article No. 4326.
https://doi.org/10.3390/cancers13174326
|
[14]
|
Saito, Y., Ikeda, M., Takahashi, T., Ishida, N., Nakano, R., Kuray-oshi, M., Nakatani, T., Toyota, K., Sadamoto, S. and Mandai, K. (2013) A Case of Advanced Gastric Cancer Effectively Treated with Weekly Paclitaxel as Neoadjuvant Chemotherapy. Gan To Kagaku Ryoho, 40, 1389-1392. (In Japa-nese).
|
[15]
|
Jin, Y., Hasuo, K., Tsuchida, K., Sawazaki, S., Hayashi, S., Rino, Y. and Masuda, M. (2011) Weekly Paclitaxel Therapy Leading to Complete Disappearance of Multiple Liver Metastases and Subsequent Surgical Resection for Advanced Gastric Cancer. Gan To Kagaku Ryoho, 38, 647-649. (In Japanese).
|
[16]
|
Wu, R., Shen, Z., Yu, N., Xu, J., Yuan, X., Ni, L., Long, Y., Tao, J. and Zhang, Y. (2019) Efficacy and Safety of Lipo-some-Paclitaxel/Liposome-Paclitaxel Combined with S-1 in 17 Advanced Gastric Cancer Patients with Poor Performance Status. Translational Cancer Research, 8, 1690-1698. https://doi.org/10.21037/tcr.2019.08.17
|
[17]
|
龚继芳, 陆明, 李洁, 李燕, 周军, 鲁智豪, 王晰程, 李健, 张小田, 沈琳. 注射用紫杉醇(白蛋白结合型)治疗进展期胃癌[J]. 北京大学学报(医学版), 2014, 46(1): 144-148.
|
[18]
|
Nishina, T., Azuma, M., Nishikawa, K., Gotoh, M., Bando, H., Sugimoto, N., Amagai, K., Chin, K., Niwa, Y., Tsuji, A., Imamura, H., Tsuda, M., Yasui, H., Fujii, H., Yamaguchi, K., Yasui, H., Hironaka, S., Shimada, K., Miwa, H., Mitome, T., Kageyama, H. and Hyodo, I. (2019) Early Tumor Shrink-age and Depth of Response in Patients with Advanced Gastric Cancer: A Retrospective Analysis of a Randomized Phase III Study of First-Line S-1 plus Oxaliplatin vs. S-1 plus Cisplatin. Gastric Cancer, 22, 138-146. https://doi.org/10.1007/s10120-018-0845-7
|
[19]
|
Iwasaki, Y., Sasako, M., Yamamoto, S., Nakamura, K., Sano, T., Katai, H., Tsujinaka, T., Nashimoto, A., Fukushima, N., Tsuburaya, A. and Gastric Cancer Surgical Study Group of Ja-pan Clinical Oncology Group (2013) Phase II Study of Preoperative Chemotherapy with S-1 and Cisplatin Followed by Gastrectomy for Clinically Resectable Type 4 and Large Type 3 Gastric Cancers (JCOG0210). Journal of Surgical On-cology, 107, 741-745.
https://doi.org/10.1002/jso.23301
|
[20]
|
Tsuburaya, A., Nagata, N., Cho, H., Hirabayashi, N., Kobayashi, M., Koji-ma, H., Munakata, Y., Fukushima, R., Kameda, Y., Shimoda, T., Oba, K. and Sakamoto, J. (2013) Phase II Trial of Paclitaxel and Cisplatin as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer. Cancer Chemotherapy and Pharmacology, 71, 1309-1314.
https://doi.org/10.1007/s00280-013-2130-0
|
[21]
|
Watanabe, T., Yoshikawa, T., Kameda, Y., Aoyama, T., Hayashi, T., Ogata, T., Cho, H., Tsuburaya, A., Morita, S., Miyashita, Y. and Sakamoto, J. (2012) Pathological Complete Re-sponse of Locally Advanced Gastric Cancer after Four Courses of Neoadjuvant Chemotherapy with Paclitaxel plus Cis-platin: Report of a Case. Surgery Today, 42, 983-987. https://doi.org/10.1007/s00595-012-0155-3
|
[22]
|
Moreira, E., Paulino, E., Ingles Garces, Á.H., Fontes Dias, M.S., Saramago, M., de Moraes Lino da Silva, F., Thuler, L.C.S. and de Melo, A.C. (2018) Efficacy of Doxorubicin after Progression on Carboplatin and Paclitaxel in Advanced or Recurrent Endometrial Cancer: A Retrospective Analysis of Patients Treated at the Brazilian National Cancer Institute (INCA). Medical Oncology, 35, Article No. 20. https://doi.org/10.1007/s12032-018-1086-7
|
[23]
|
Okuda, K., Yano, M., Tatematsu, T., Nakamae, K., Yamada, T., Kasugai, T., Nishida, T., Sano, M., Moriyama, S., Haneda, H., Kawano, O. and Nakanishi, R. (2018) S-1 vs. Paclitaxel plus Carboplatin as Adjuvant Chemotherapy for Completely Resected Stage II/IIIA Non-Small-Cell Lung Cancer. Molecular and Clinical Oncology, 8, 73-79.
https://doi.org/10.3892/mco.2017.1481
|
[24]
|
Yazawa, H., Hiraiwa, T., Ito, F. and Fujimori, K. (2017) Long-Term Recurrence-Free Survival of a Patient with Advanced Pure Primary Ovarian Squamous Cell Carcinoma Treated with Dose-Dense Paclitaxel Combined with Carboplatin. Obstetrics & Gynecology Science, 60, 587-592. https://doi.org/10.5468/ogs.2017.60.6.587
|
[25]
|
彭涛, 娄展, 张育, 王国强, 曹铭富, 高强, 李曙光. 紫杉醇联合卡铂新辅助化疗治疗III期胃癌的疗效及安全性[J]. 现代肿瘤医学, 2019, 27(10): 1765-1768. https://doi.org/10.3969/j.issn.1672-4992.2019.10.025
|
[26]
|
苏卓彬, 李曙光, 任惠敏, 王国强, 黄迪, 王晓元, 籍阳阳, 赵轶峰, 杨永江. 紫杉醇联合卡铂单周化疗方案与奥沙利铂联合卡培他滨方案对III期胃癌患者的疗效及安全性比较[J]. 中国医药, 2020, 15(10): 1567-1571.
|
[27]
|
彭巍, 谭盐梅, 赵晔. 紫杉醇联合卡铂单周化疗方案与奥沙利铂联合卡培他滨方案对III期胃癌患者的疗效及安全性对比[J]. 中国处方药, 2021, 19(6): 91-92.
|
[28]
|
廖立潇, 石大友, 欧阳俊. 奥沙利铂联合卡培他滨与紫杉醇联合卡铂方案治疗老年进展期胃癌的效果及毒副反应对比[J]. 天津药学, 2019, 31(3): 48-49+68.
|
[29]
|
王国强, 苏卓彬, 胡瑞霞, 杨永江, 赵轶峰, 籍阳阳, 彭涛, 李曙光. 紫杉醇联合卡铂单周方案与SOX方案用于胃癌新辅助化疗的比较[J]. 山东医药, 2017, 57(33): 84-86.
|
[30]
|
刘京京. 紫杉醇卡铂单周方案对III期胃癌患者的近期疗效和安全性的分析[J]. 世界复合医学, 2018, 4(4): 51-53.
|
[31]
|
Zhang, X., Liang, H., Li, Z., Xue, Y., Wang, Y., Zhou, Z., Yu, J., Bu, Z., Chen, L., Du, Y., et al. (2021) Perioperative or Postoperative Adjuvant Oxaliplatin with S-1 versus Adjuvant Oxaliplatin with Capecitabine in Patients with Locally Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma Undergoing D2 Gastrectomy (RESOLVE): An Open-Label, Superiority and Non-Inferiority, Phase 3 Randomised Controlled Trial. The Lancet On-cology, 22, 1081-1092. https://doi.org/10.1016/S1470-2045(21)00297-7
|
[32]
|
Alcindor, T. and Beauger, N. (2011) Oxaliplatin: A Review in the Era of Molecularly Targeted Therapy. Current Oncology, 18, 18-25. https://doi.org/10.3747/co.v18i1.708
|
[33]
|
Misset, J.L., Bleiberg, H., Sutherland, W., Bekradda, M. and Cvitkovic, E. (2000) Oxaliplatin Clinical Activity: A Review. Critical Reviews in Oncology/Hematology, 35, 75-93. https://doi.org/10.1016/S1040-8428(00)00070-6
|
[34]
|
徐倩. 紫杉醇和奥沙利铂联合方案一线治疗晚期胃癌的临床观察[D]: [硕士学位论文]. 福州: 福建医科大学, 2014.
|
[35]
|
毛爱芹, 张育荣, 苏爱江, 梁平, 魏广占. 奥沙利铂联合紫杉醇脂质体治疗晚期胃癌的疗效分析[J]. 癌症进展, 2018, 16(6): 715-718.
|
[36]
|
朱万里, 王鹏, 王晖, 王红丽, 程鹏, 苟菲. 白蛋白结合型紫杉醇联合奥沙利铂一线治疗晚期胃癌的临床观察[J]. 中国药房, 2022, 33(13): 1630-1634.
|
[37]
|
冯继. 紫杉醇(白蛋白结合型)联合奥沙利铂治疗晚期胃癌的临床观察[J]. 罕少疾病杂志, 2022, 29(2): 76-77+84.
|
[38]
|
Fushida, S., Kinoshita, J., Kaji, M., Hirono, Y., Goda, F., Yagi, Y., Oyama, K., Sudo, Y., Watanabe, Y., Fujimura, T. and Society for Study of Peritoneal Carcinomatosis in Gastric Cancer (2013) Phase I/II Study of Intraperitoneal Docetaxel plus S-1 for the Gastric Cancer Patients with Peritoneal Carcinomatosis. Cancer Chemo-therapy and Pharmacology, 71, 1265-1272. https://doi.org/10.1007/s00280-013-2122-0
|
[39]
|
常占国, 徐全晓. 紫杉醇联合奥沙利铂治疗老年晚期胃癌[J]. 现代肿瘤医学, 2012, 20(8): 1669-1671.
|
[40]
|
杜彬, 曹磊, 李小燕. 紫杉醇联合奥沙利铂与卡培他滨联合奥沙利铂治疗晚期胃癌的疗效比较[J]. 福建医药杂志, 2013, 35(6): 80-83.
|
[41]
|
黄涛, 王敏. 紫杉醇联合奥沙利铂与卡培他滨联合奥沙利铂治疗晚期胃癌的疗效比较[J]. 中国现代医生, 2017, 55(33): 92-94.
|
[42]
|
王襄瑜, 薛芳沁, 黄良祥. 紫杉醇联合奥沙利铂和替吉奥在进展期胃癌新辅助化疗中的应用[J]. 海峡药学, 2015, 27(10): 107-109.
|
[43]
|
张晶, 李萍, 张永. 紫杉醇脂质体联合奥沙利铂和替吉奥治疗晚期胃癌临床观察[J]. 中国医药科学, 2016, 6(10): 195-197.
|
[44]
|
黄向东, 牛强, 郭伟. 奥沙利铂联合紫杉醇脂质体和替吉奥治疗晚期胃癌的临床疗效及可行性研究[J]. 中国药物与临床, 2017, 17(3): 375-377.
|
[45]
|
赵怡, 张正筠, 姚敬, 杨喆. 紫杉醇联合奥沙利铂及S-1的新辅助化疗方案对进展期胃癌治疗效果评价[J]. 现代肿瘤医学, 2020, 28(19): 3378-3382.
|
[46]
|
朱之忆. 胃癌新辅助化疗二药及三药疗效评价[D]: [硕士学位论文]. 乌鲁木齐: 新疆医科大学, 2020.
https://doi.org/10.27433/d.cnki.gxyku.2020.000223
|
[47]
|
刘子田, 王晓阳, 祝新, 毛佳佳, 刘志, 武群政, 孙富云, 姚伦锦, 金明新. 白蛋白结合型紫杉醇联合奥沙利铂和替吉奥在局部不可切除的进展期胃癌转化治疗中的应用[J]. 中国现代普通外科进展, 2021, 24(5): 374-377+383.
|
[48]
|
曲建军, 石毅然, 刘法荣, 马世庆, 马富懿. 紫杉醇联合FOLFOX4方案新辅助化疗在进展期胃癌中的临床应用[J]. 中华胃肠外科杂志, 2010, 13(9): 664-667.
|
[49]
|
王金泗, 林孟波, 薛芳沁, 陈晓耕. POX方案新辅助化疗在进展期胃癌中的临床应用[J]. 福建医药杂志, 2012, 34(1): 91-93.
|
[50]
|
周志峰, 叶炆凤. 奥沙利铂、卡培他滨联合紫杉醇脂质体新辅助化疗治疗进展期胃癌的临床效果[J]. 临床合理用药杂志, 2022, 15(23): 69-72. https://doi.org/10.15887/j.cnki.13-1389/r.2022.23.021
|